Ezogabine, an activator of Kv7.2–5 subunit-containing channels that is approved for epilepsy in adults, has been shown to reverse effects of KCNQ2 encephalopathy variants in patch clamp experiments (Miceli et al., 2013; Orhan et al., 2014; Soldovieri et al., 2016). Here, KCNQ2 is linked to Encephalopathy.